These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 16379606

  • 1. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    Toni TD, Masquelier B, Lazaro E, Dore-Mbami M, Ba-Gomis FO, Téa-Diop Y, Kouakou K, Diby J, Sia E, Soppi S, Essien S, Schrive MH, Pinson P, Chenal H, Fleury HJ.
    AIDS Res Hum Retroviruses; 2005 Dec; 21(12):1031-4. PubMed ID: 16379606
    [Abstract] [Full Text] [Related]

  • 2. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    Kurle SN, Gangakhedkar RR, Sen S, Hayatnagarkar SS, Tripathy SP, Paranjape RS.
    AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993
    [Abstract] [Full Text] [Related]

  • 3. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
    Jones D, Parkin N, Hudelson SE, Guay LA, Musoke P, Mmiro F, Jackson JB, Eshleman SH.
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):319-24. PubMed ID: 15943576
    [Abstract] [Full Text] [Related]

  • 4. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
    Samuel R, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A, Gordon M.
    J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
    [Abstract] [Full Text] [Related]

  • 5. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
    Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, Mmiro F, Jackson JB.
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):595-9. PubMed ID: 15242535
    [Abstract] [Full Text] [Related]

  • 6. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.
    Clin Infect Dis; 2008 Feb 15; 46(4):611-21. PubMed ID: 18197758
    [Abstract] [Full Text] [Related]

  • 7. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
    Chaix ML, Ekouevi DK, Rouet F, Tonwe-Gold B, Viho I, Bequet L, Peytavin G, Toure H, Menan H, Leroy V, Dabis F, Rouzioux C, Agence Nationale de Recherches sur le SIDA Ditrame Plus Study Group.
    J Infect Dis; 2006 Feb 15; 193(4):482-7. PubMed ID: 16425126
    [Abstract] [Full Text] [Related]

  • 8. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB.
    AIDS; 2001 Oct 19; 15(15):1951-7. PubMed ID: 11600822
    [Abstract] [Full Text] [Related]

  • 9. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
    Persaud D, Bedri A, Ziemniak C, Moorthy A, Gudetta B, Abashawl A, Mengistu Y, Omer SB, Isehak A, Kumbi S, Adamu R, Lulseged S, Ashworth R, Hassen E, Ruff A, Ethiopian Swen Study Team.
    AIDS Res Hum Retroviruses; 2011 Aug 19; 27(8):823-9. PubMed ID: 21241214
    [Abstract] [Full Text] [Related]

  • 10. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
    Chaix ML, Ekouevi DK, Peytavin G, Rouet F, Tonwe-Gold B, Viho I, Bequet L, Amani-Bosse C, Menan H, Leroy V, Rouzioux C, Dabis F.
    Antimicrob Agents Chemother; 2007 Mar 19; 51(3):896-901. PubMed ID: 17178792
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
    Frank M, von Kleist M, Kunz A, Harms G, Schütte C, Kloft C.
    Antimicrob Agents Chemother; 2011 Dec 19; 55(12):5529-40. PubMed ID: 21947390
    [Abstract] [Full Text] [Related]

  • 13. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    van Zyl GU, Claassen M, Engelbrecht S, Laten JD, Cotton MF, Theron GB, Preiser W.
    J Med Virol; 2008 Jun 19; 80(6):942-6. PubMed ID: 18428139
    [Abstract] [Full Text] [Related]

  • 14. Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
    Pilger D, Hauser A, Kuecherer C, Mugenyi K, Kabasinguzi R, Somogyi S, Harms G, Kunz A.
    Antivir Ther; 2011 Jun 19; 16(1):109-13. PubMed ID: 21311114
    [Abstract] [Full Text] [Related]

  • 15. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    Servais J, Lambert C, Karita E, Vanhove D, Fischer A, Baurith T, Schmit JC, Schneider F, Hemmer R, Arendt V.
    AIDS Res Hum Retroviruses; 2004 Mar 19; 20(3):279-83. PubMed ID: 15117451
    [Abstract] [Full Text] [Related]

  • 16. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.
    Kassaye S, Lee E, Kantor R, Johnston E, Winters M, Zijenah L, Mateta P, Katzenstein D.
    AIDS Res Hum Retroviruses; 2007 Aug 19; 23(8):1055-61. PubMed ID: 17725424
    [Abstract] [Full Text] [Related]

  • 17. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006.
    Toni Td, Masquelier B, Minga A, Anglaret X, Danel C, Coulibaly A, Chenal H, Dabis F, Salamon R, Fleury HJ, Primo-CI ANRS 1220 Study Group.
    AIDS Res Hum Retroviruses; 2007 Sep 19; 23(9):1155-60. PubMed ID: 17919113
    [Abstract] [Full Text] [Related]

  • 18. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
    Kuhn L, Sinkala M, Kankasa MP, Kasonde P, Thea DM, Aldrovandi GM.
    J Acquir Immune Defic Syndr; 2006 Jun 19; 42(2):260-2. PubMed ID: 16760802
    [No Abstract] [Full Text] [Related]

  • 19. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
    Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, Jackson JB, Guay LA, Eshleman SH.
    J Infect Dis; 2007 Mar 01; 195(5):711-5. PubMed ID: 17262714
    [Abstract] [Full Text] [Related]

  • 20. Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria.
    Ojesina AI, Mullins C, Imade G, Samuels J, Sankalé JL, Pam S, Sagay S, Idoko J, Kanki PJ.
    AIDS Res Hum Retroviruses; 2007 Dec 01; 23(12):1587-92. PubMed ID: 18160018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.